Press Release

<< Back
Sep 08, 2020

Aravive to Participate in Upcoming Virtual Investor Conferences in September

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in September:

  • Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 15, 2020, at 3:20 p.m. ET
  • H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020, at 1:00 p.m. ET

Live webcasts and audio archives of the presentations will be available at Archived replays of the webcasts will be available for 90 days following the presentations.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and selected 15 mg/kg as the dose for the next potential pivotal trial. Analysis of all safety data to date showed that AVB-500 has been generally well-tolerated with no dose-limiting toxicities or unexpected safety signals. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company also intends to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year. For more information, please visit

Sheryl Seapy, W2O
(949) 903-4750

Luke Heagle, W2O
(910) 726-1372


Aravive Logo.png

Source: Aravive, Inc.